Corcept (NASDAQ: CORT) grants director 12,500 stock options vesting in 2026

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics director David L. Mahoney reported a new stock option grant. He received options to acquire 12,500 shares of Corcept common stock at an exercise price of $59.69 per share, expiring on May 21, 2036.

The options were granted as compensation and involve no open-market buying or selling. According to the terms, they become exercisable in equal monthly installments over one year starting on May 21, 2026, contingent on his continued service on each monthly vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MAHONEY DAVID L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	12,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 12,500 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 12,500 options Exercise price: $59.69 per share Expiration date: May 21, 2036 +2 more

5 metrics

Stock options granted 12,500 options Grant to director David L. Mahoney

Exercise price $59.69 per share Stock option exercise price

Expiration date May 21, 2036 Option term end

Underlying shares 12,500 shares Common stock underlying options

Vesting schedule start May 21, 2026 Monthly vesting over one year

Key Terms

Stock Option (right to buy), exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "59.6900" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-05-21T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Stock""

vesting financial

"Exercisable ratably in equal installments on each monthly anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

05/26/2026 - 05:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAHONEY DAVID L

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

CALIFORNIA

94065

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$59.69	05/21/2026		A		12,500		⁽¹⁾	05/21/2036	Common Stock	12,500	$0	12,500	D

Explanation of Responses:

1. Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for David L. Mahoney	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Corcept Therapeutics (CORT) director David L. Mahoney report on this Form 4?

David L. Mahoney reported receiving a grant of stock options for 12,500 shares of Corcept common stock. These options were awarded as compensation, not purchased in the market, and give him the right to buy shares at a fixed exercise price in the future.

How many Corcept (CORT) shares are covered by Mahoney’s new stock options?

The grant covers options on 12,500 shares of Corcept common stock. This figure represents the total number of underlying shares he may purchase if he exercises all the options once they have vested and before they expire.

What is the exercise price of David Mahoney’s Corcept (CORT) stock options?

The options have an exercise price of $59.69 per share, meaning Mahoney can buy Corcept common stock at $59.69 once options vest. This price is fixed in the grant and does not change over the option’s life.

When do David Mahoney’s new Corcept (CORT) stock options vest?

The options vest in equal monthly installments over one year starting May 21, 2026. Vesting each month is conditional on Mahoney’s continued service on the respective vesting dates, aligning the award with ongoing board tenure.

When do David Mahoney’s Corcept (CORT) stock options expire?

The options expire on May 21, 2036, giving Mahoney up to ten years after grant to exercise vested options. After the expiration date, any unexercised options become worthless and can no longer be used to buy shares.

Does this Corcept (CORT) Form 4 show any open-market buying or selling by David Mahoney?

No, the Form 4 only shows a grant of stock options classified as an acquisition award. There are no open-market purchases or sales of Corcept common stock reported in this filing, making it a routine compensation-related transaction.